Anta Gkelou

Anta Gkelou is a Partner in the Sofinnova Capital Strategy at Sofinnova Partners, having joined the firm in 2017 and promoted to Partner in 2024.

Anta's expertise lies in investing in early-stage biotech companies, with a strong focus on biopharmaceuticals and medical devices.

Anta plays a key role in company creation, notably co-founding Bionyra in 2025, a biotech focused on developing treatments for immune-mediated inflammatory diseases.

Prior to Sofinnova Partners, Anta served as an immunology scientist at Danone Nutricia, where Anta was involved in translational research and development of prebiotic and probiotic products for immune resilience.

Anta holds a PhD from Imperial College London, where research focused on oxidative stress-driven steroid insensitivity in COPD, and completed post-doctoral studies at INSERM, investigating cardiomyocyte function post myocardial infarction.

Anta is currently focused on identifying and backing groundbreaking scientific discoveries to build companies with transformative effects on patients' lives.

Bio is AI generated & may not be accurate.